Atrial and Brain Natriuretic Peptides- Benefits and Limits of their use in Cardiovascular Diseases.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Bentham Science Publishers Country of Publication: United Arab Emirates NLM ID: 101261935 Publication Model: Print Cited Medium: Internet ISSN: 1875-6557 (Electronic) Linking ISSN: 1573403X NLM ISO Abbreviation: Curr Cardiol Rev Subsets: MEDLINE
    • Publication Information:
      Original Publication: Saif Zone, Sharjah, U.A.E. ; San Francisco, CA : Bentham Science Publishers, 2005-
    • Subject Terms:
      Cardiovascular Diseases/*genetics ; Hemodynamics/*genetics ; Natriuretic Peptide, Brain/*metabolism ; Natriuretic Peptides/*metabolism; Cardiovascular Diseases/metabolism ; Humans
    • Abstract:
      Natriuretic peptides, produced by cardiac myocytes, are regulators of the intravascular volume and blood pressure, and also exhibit neuroendocrine, metabolic and growth controlling effects. In heart failure, their synthesis increases exponentially as part of the neuroendocrine activation, but their beneficial effects are diminished. The paper reviews relevant data about their role as diagnosis and prognosis markers in heart failure, the hemodynamic and clinical benefits of their use as therapy in heart failure, together with the main adverse effects. Peptides non-specifically increase in extracardiac pathology and the literature reveals the mechanisms of increase, significance and threshold values to exclude cardiac dysfunction.
      (Copyright© Bentham Science Publishers; For any queries, please email at [email protected].)
    • References:
      J Cell Biol. 1964 Oct;23:151-72. (PMID: 14228508)
      Br J Clin Pharmacol. 2016 May;81(5):878-90. (PMID: 26663387)
      Eur J Heart Fail. 2017 Feb;19(2):167-176. (PMID: 27766748)
      Am Heart J. 2006 Nov;152(5):941-8. (PMID: 17070165)
      Nefrologia. 2015;35(3):227-33. (PMID: 26299165)
      Am J Cardiol. 2017 Jul 15;120(2):181-185. (PMID: 28599802)
      Int J Cardiol. 2008 May 7;126(1):28-31. (PMID: 17477984)
      Card Fail Rev. 2016 May;2(1):14-19. (PMID: 28848655)
      Clin Chem. 2007 Aug;53(8):1511-9. (PMID: 17586595)
      Exp Med Surg. 1956;14(2-3):99-112. (PMID: 13365605)
      Eur Rev Med Pharmacol Sci. 2010 Oct;14(10):855-60. (PMID: 21222371)
      BMJ. 2015 Mar 04;350:h910. (PMID: 25740799)
      Intensive Care Med. 2008 Dec;34(12):2147-56. (PMID: 18626627)
      J Am Coll Cardiol. 2006 Feb 21;47(4):742-8. (PMID: 16487838)
      Eur J Heart Fail. 2017 Jan;19(1):129-137. (PMID: 27868321)
      JACC Heart Fail. 2013 Jun;1(3):192-9. (PMID: 24621869)
      J Am Coll Cardiol. 2002 Sep 4;40(5):976-82. (PMID: 12225726)
      Clin Chem. 2005 May;51(5):925-6. (PMID: 15855677)
      JACC Heart Fail. 2017 Jul;5(7):471-482. (PMID: 28662936)
      Sports (Basel). 2016 May 31;4(2):. (PMID: 29910280)
      Eur Heart J. 2016 Jul 14;37(27):2129-2200. (PMID: 27206819)
      Int J Chron Obstruct Pulmon Dis. 2017 Apr 13;12:1183-1189. (PMID: 28458528)
      FASEB J. 2000 Jul;14(10):1345-51. (PMID: 10877827)
      Eur Heart J. 2012 Aug;33(16):2001-6. (PMID: 21292681)
      J Card Fail. 2002 Jun;8(3):149-54. (PMID: 12140807)
      Am J Physiol Heart Circ Physiol. 2006 Jan;290(1):H17-29. (PMID: 16373590)
      Congest Heart Fail. 2008 Jul-Aug;14(4 Suppl 1):25-9. (PMID: 18772630)
      Circulation. 2002 Feb 5;105(5):595-601. (PMID: 11827925)
      JACC Cardiovasc Imaging. 2009 Feb;2(2):216-25. (PMID: 19356559)
      JAMA. 2013 Dec 18;310(23):2533-43. (PMID: 24247300)
      Cardiovasc Res. 2002 Aug 1;55(2):375-84. (PMID: 12123777)
      Physiol Res. 2009;58(2):171-177. (PMID: 18380534)
      Am Heart J. 1999 Dec;138(6 Pt 1):1126-32. (PMID: 10577444)
      Circulation. 2005 Mar 29;111(12):1487-91. (PMID: 15781736)
      J Am Coll Cardiol. 2007 Nov 6;50(19):1835-40. (PMID: 17980248)
      BMJ. 2005 Mar 19;330(7492):625. (PMID: 15774989)
      J Am Coll Cardiol. 2004 Feb 4;43(3):416-22. (PMID: 15013124)
      Nature. 1988 Mar 3;332(6159):78-81. (PMID: 2964562)
      Pharmacol Ther. 2014 Oct;144(1):12-27. (PMID: 24780848)
      Life Sci. 1981 Jan 5;28(1):89-94. (PMID: 7219045)
      Clin Sci (Lond). 2016 Jan;130(2):57-77. (PMID: 26637405)
      J Clin Invest. 1991 Apr;87(4):1402-12. (PMID: 1849149)
      Lancet. 2000 Apr 1;355(9210):1126-30. (PMID: 10791374)
      Eur J Clin Invest. 2006 Jan;36(1):8-15. (PMID: 16403004)
      JACC Basic Transl Sci. 2016 Dec;1(7):557-567. (PMID: 28497128)
      Am J Hematol. 2005 Nov;80(3):174-80. (PMID: 16247751)
      J Am Coll Cardiol. 2001 Jun 1;37(7):1781-7. (PMID: 11401111)
      Am J Clin Pathol. 2006 Oct;126(4):506-12. (PMID: 16938661)
      JAMA. 2017 Aug 22;318(8):713-720. (PMID: 28829876)
      BMJ Open. 2016 Jan 06;6(1):e008545. (PMID: 26739721)
      N Engl J Med. 2011 Jul 7;365(1):32-43. (PMID: 21732835)
      Handb Exp Pharmacol. 2009;(191):341-66. (PMID: 19089336)
      J Gerontol A Biol Sci Med Sci. 1996 May;51(3):M95-101. (PMID: 8630708)
    • Contributed Indexing:
      Keywords: Natriuretic peptides; cardiac dysfunction; cardiovascular diseases; heart failure; nesiritide; sacubitril- valsartan.
    • Accession Number:
      0 (Natriuretic Peptides)
      114471-18-0 (Natriuretic Peptide, Brain)
    • Publication Date:
      Date Created: 20190328 Date Completed: 20191115 Latest Revision: 20210526
    • Publication Date:
      20240829
    • Accession Number:
      PMC8142359
    • Accession Number:
      10.2174/1573403X15666190326150550
    • Accession Number:
      30914031